Key result
Doxorubicin-based chemotherapy in pediatric patients with acute lymphoblastic leukemia was associated with a significant increase in troponin I levels from baseline to after the last dose (p<0.0001).
Why the study?
Do troponin I and H-FABP detect subclinical cardiotoxicity in pediatric patients with acute lymphoblastic leukemia receiving doxorubicin?
Population
20 pediatric patients newly diagnosed with acute lymphoblastic leukemia and treated according to BFM-ALL IC…
Design
Cohort
Follow-up
1 year after diagnosis
Authors
Loading...
Supports troponin I as a biomarker for early subclinical cardiotoxicity in pediatric acute lymphoblastic leukemia.
Observational (n=20)
Do troponin I and H-FABP detect subclinical cardiotoxicity in pediatric patients with acute lymphoblastic leukemia receiving doxorubicin?
Absolute Event Rate: 0.0285% vs 0.0125%
p-value: p=<0.0001
Troponin I, but not H-FABP, is a useful biomarker for detecting early subclinical doxorubicin-induced cardiac damage in pediatric patients with acute lymphoblastic leukemia.
Radu et al. (2017) conducted an observational in Acute lymphoblastic leukaemia (n=20). Doxorubicin-based chemotherapy vs. Baseline (pre-treatment) was evaluated on Troponin I (TnI) level change from baseline to after the last dose of anthracycline (p=<0.0001). Doxorubicin-based chemotherapy in pediatric patients with acute lymphoblastic leukemia was associated with a significant increase in troponin I levels from baseline to after the last dose (p<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: